Refine by
Lung Tumor Articles & Analysis
8 news found
"The emerging data being presented at ESMO are encouraging, as treatment with rigosertib plus nivolumab led to both complete and partial responses in patients with KRAS-mutated lung cancers who failed prior ICI therapy,” said Dr Rajwanth Veluswamy, the principal investigator of the study. ...
The American Lung Association recently released its 2021 State of Lung Cancer report. ...
Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific's Oncomine Dx Target Test as a companion diagnostic (CDx) to help identify non-small cell lung cancer (NSCLC) patients whose tumors carry epidermal growth factor receptor (EGFR) Exon20-insertion mutations for potential treatment with RYBREVANT (amivantamab-vmjw)*, ...
A plug&play interface between the two technologies will allow physiologically relevant exposure to complex aerosols in the background of an in vivo-like organization and breathing performance of the human lungs. The novel integrated HUMIMIC–InHALES test platform will allow acute and subchronic tests on lung models in combination with miniaturized human ...
“These data are very exciting because our HLA-independent TCR targeting mesothelin induced complete regression in a mouse tumor xenograft model and also outperformed a TRuC construct that we developed in-house,” said Karen Miller, SVP, Pipeline Research. ...
The study, “T-SIGn cancer gene therapy and anti-EGFR CAR-T cells synergize in combination therapy to clear A549 lung tumor xenografts”, assessed anti-tumor synergy between PsiOxus’ T-SIGn® vectors and an anti-epidermal growth factor receptor (EGFR) chimeric antigen receptor (CAR)-T cell therapy from bluebird bio in xenograft ...
The program is intended to launch in three categories: Population health screening and predictive analytics for conditions such as coronary arterial disease, stroke prevention and osteoporosis; Post-acute triage for urgent conditions such as pneumothorax, acute fractures and pneumonia (including COVID-19); and Routine peer review and quality assurance cases for conditions such as ...
Food and Drug Administration has approved a new test that can identify PD-L1 expression levels on the surface of non-small cell lung cancer tumor cells and provide information on the survival benefit with OPDIVO® (nivolumab) for patients with non-squamous NSCLC. ...